Pregabalin for the treatment of generalized anxiety disorder: an update

David S Baldwin,1–3 Khalil Ajel,3 Vasilios G Masdrakis,4 Magda Nowak,1 Rizwan Rafiq31Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK; 2Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Afr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/69dadd853ece42a99a4e5f92f6a1d795
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:69dadd853ece42a99a4e5f92f6a1d795
record_format	dspace
spelling	oai:doaj.org-article:69dadd853ece42a99a4e5f92f6a1d7952021-12-02T00:57:17ZPregabalin for the treatment of generalized anxiety disorder: an update1176-63281178-2021https://doaj.org/article/69dadd853ece42a99a4e5f92f6a1d7952013-06-01T00:00:00Zhttp://www.dovepress.com/pregabalin-for-the-treatment-of-generalized-anxiety-disorder-an-update-a13442https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021David S Baldwin,1–3 Khalil Ajel,3 Vasilios G Masdrakis,4 Magda Nowak,1 Rizwan Rafiq31Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK; 2Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa; 3Southern Health NHS Foundation Trust, Southampton, UK; 4First Department of Psychiatry, Eginition Hospital, Athens University Medical School, Athens, GreeceAbstract: A previous review summarized what was then known about the potential role of pregabalin in the treatment of patients with generalized anxiety disorder (GAD): this review provides an update on its pharmacological properties and presumed mechanism of action, the liability for abuse, and efficacy and tolerability in patients with GAD. Pregabalin has a similar molecular structure to the inhibitory neurotransmitter gamma amino butyric acid (GABA) but its mechanism of action does not appear to be mediated through effects on GABA. Instead, its anxiolytic effects may arise through high-affinity binding to the alpha-2-delta sub-unit of the P/Q type voltage-gated calcium channel in “over-excited” presynaptic neurons, thereby reducing the release of excitatory neurotransmitters such as glutamate. The findings of randomized controlled trials and meta-analyses together indicate that pregabalin is efficacious in both acute treatment and relapse prevention in GAD, with some evidence of an early onset of effect, and broad efficacy in reducing the severity of psychological and physical symptoms of anxiety. It also has efficacy as an augmenting agent after non-response to antidepressant treatment in GAD. Continuing vigilance is needed in assessing its potential abuse liability but the tolerability profile of pregabalin may confer some advantages over other pharmacological treatments in the short term for treatment in patients with GAD.Keywords: generalized anxiety disorder, efficacy, tolerability, pregabalinBaldwin DSAjel KMasdrakis VGNowak MRafiq RDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 883-892 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Baldwin DS Ajel K Masdrakis VG Nowak M Rafiq R Pregabalin for the treatment of generalized anxiety disorder: an update
description	David S Baldwin,1–3 Khalil Ajel,3 Vasilios G Masdrakis,4 Magda Nowak,1 Rizwan Rafiq31Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK; 2Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa; 3Southern Health NHS Foundation Trust, Southampton, UK; 4First Department of Psychiatry, Eginition Hospital, Athens University Medical School, Athens, GreeceAbstract: A previous review summarized what was then known about the potential role of pregabalin in the treatment of patients with generalized anxiety disorder (GAD): this review provides an update on its pharmacological properties and presumed mechanism of action, the liability for abuse, and efficacy and tolerability in patients with GAD. Pregabalin has a similar molecular structure to the inhibitory neurotransmitter gamma amino butyric acid (GABA) but its mechanism of action does not appear to be mediated through effects on GABA. Instead, its anxiolytic effects may arise through high-affinity binding to the alpha-2-delta sub-unit of the P/Q type voltage-gated calcium channel in “over-excited” presynaptic neurons, thereby reducing the release of excitatory neurotransmitters such as glutamate. The findings of randomized controlled trials and meta-analyses together indicate that pregabalin is efficacious in both acute treatment and relapse prevention in GAD, with some evidence of an early onset of effect, and broad efficacy in reducing the severity of psychological and physical symptoms of anxiety. It also has efficacy as an augmenting agent after non-response to antidepressant treatment in GAD. Continuing vigilance is needed in assessing its potential abuse liability but the tolerability profile of pregabalin may confer some advantages over other pharmacological treatments in the short term for treatment in patients with GAD.Keywords: generalized anxiety disorder, efficacy, tolerability, pregabalin
format	article
author	Baldwin DS Ajel K Masdrakis VG Nowak M Rafiq R
author_facet	Baldwin DS Ajel K Masdrakis VG Nowak M Rafiq R
author_sort	Baldwin DS
title	Pregabalin for the treatment of generalized anxiety disorder: an update
title_short	Pregabalin for the treatment of generalized anxiety disorder: an update
title_full	Pregabalin for the treatment of generalized anxiety disorder: an update
title_fullStr	Pregabalin for the treatment of generalized anxiety disorder: an update
title_full_unstemmed	Pregabalin for the treatment of generalized anxiety disorder: an update
title_sort	pregabalin for the treatment of generalized anxiety disorder: an update
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/69dadd853ece42a99a4e5f92f6a1d795
work_keys_str_mv	AT baldwinds pregabalinforthetreatmentofgeneralizedanxietydisorderanupdate AT ajelk pregabalinforthetreatmentofgeneralizedanxietydisorderanupdate AT masdrakisvg pregabalinforthetreatmentofgeneralizedanxietydisorderanupdate AT nowakm pregabalinforthetreatmentofgeneralizedanxietydisorderanupdate AT rafiqr pregabalinforthetreatmentofgeneralizedanxietydisorderanupdate
_version_	1718403388690923520

Pregabalin for the treatment of generalized anxiety disorder: an update

Ejemplares similares